Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,896 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Sale · Disposed 1,322 · Balance 24,896 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025. |
| Common SharesSEC Table I · non-derivative | IndirectSee Note | 4,902 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,902 F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.
F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2018 Filed Jun 15, 2018 23:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,856 | $8.30 | $23,704.80 |
DisclosureSEC source: 0001171843-18-004695 · formfour.xml · nonDerivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,402 F2 · price: Represents the closing price of the Company's common shares in U.S. dollars on June 13, 2018, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 23:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 8,230 | $3.70 | $30,451.00 |
DisclosureSEC source: 0001171843-18-004695 · formfour.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 20:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001171843-18-004458 · form4.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-03 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:07 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Stock | 7,500 | $2.78 | $20,835.75 |
DisclosureSEC source: 0001171843-17-005072 · f4_patou081417.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 12,500 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.7769 to $2.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 23:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Stock | 5,000 | $3.00 | $15,002.50 |
DisclosureSEC source: 0001171843-17-004960 · formfour.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 5,000 F1 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 21:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001171843-17-003445 · formfour.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Shares · 3,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:52 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,345 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001171843-16-013554 · form4patou.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,345 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2009. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:52 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 4,403 | $7.90 | $34,783.70 |
DisclosureSEC source: 0001171843-16-013554 · form4patou.xml · nonDerivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,028 F2 · shares: Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person in favor of the underwriters of the Company's Public Offering in September 2016 (the "Lock-up"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up. F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 5, 2016, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:52 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 12,345 | $3.21 | $39,627.45 |
DisclosureSEC source: 0001171843-16-013554 · form4patou.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.